SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
RedHill Biopharma Ltd. Commences a Pivotal Bioequivalence Trial with RHB-103 (An Oral Thin Film for the Treatment of Migraine); Subjects' Recruitment Completed; First Dose Administered; Results Expected within Months